What you should know:
1. WuXi developed the biologics conjugation center in June 2018.
2. The expanded center will span 5.5 acres and will allow the company to commercially manufacture antibody-drug conjugate products.
4. WuXi is currently developing more than 20 antibody-drug conjugates.
More articles on biologics:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
